Despite the proven benefits of thrombolytic therapy in acute ischemic stroke both in acute and long-term outcomes, patients arriving as a CTA are receiving this treatment less frequently.16 Documented contraindications to thrombolytics, such as unknown last known well time, factor Xa use, or NIHSS < 6 accounted for 22.4% of ischemic stroke patients in the CTA group who did not receive thrombolytics. The gene discussed is F10; the disease is ischemic stroke.